Experimental Hematology
Volume 37, Issue 1 , Pages 65-77 , January 2009

RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias

  • Suzanne G. Usher

      Affiliations

    • Small Animal Teaching Hospital, University of Liverpool, The Leahurst Campus, Neston, Wirral, UK
    • ,
  • Alan D. Radford

      Affiliations

    • Small Animal Teaching Hospital, University of Liverpool, The Leahurst Campus, Neston, Wirral, UK
    • ,
  • Elizabeth J. Villiers

      Affiliations

    • Department of Clinical Veterinary Medicine, Queen's Veterinary School Hospital, University of Cambridge, Cambridge, UK
    • ,
  • Laura Blackwood

      Affiliations

    • Small Animal Teaching Hospital, University of Liverpool, The Leahurst Campus, Neston, Wirral, UK
    • Corresponding Author InformationOffprint requests to: Laura Blackwood, B.V.M.S., Ph.D., M.V.M., Cert. V.R. Dip. E.C.V.I.M.-C.A. (Onc.), M.R.C.V.S., Small Animal Teaching Hospital, Leahurst, Chester High Road, Neston, Wirral, CH64 7TE, UK

Received 14 July 2008 ,Revised 8 September 2008 ,Accepted 8 September 2008.

References 

  1. Dorn CR, Taylor DO, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am J Vet Res. 1967;28:993–1001
  2. Vernau W, Moore PF. An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. Vet Immunol Immunopathol. 1999;69:145–164
  3. Villiers E, Baines S, Law AM, Mallows V. Identification of acute myeloid leukemia in dogs using flow cytometry with myeloperoxidase, MAC387, and a canine neutrophil-specific antibody. Vet Clin Pathol. 2006;35:55–71
  4. Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001;171:1–10
  5. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–465
  6. Bos JL. ras Oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  7. Browett PJ, Norton JD. Analysis of ras gene mutations and methylation state in human leukemias. Oncogene. 1989;4:1029–1036
  8. Barletta E, Gorini G, Vineis P, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25:749–755
  9. Miyauchi J, Asada M, Sasaki M, Tsunematsu Y, Kojima S, Mizutani S. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83:2248–2254
  10. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood. 1990;76:1214–1219
  11. Richter A, Murua Escobar H, et al. RAS gene hot-spot mutations in canine neoplasias. J Hered. 2005;96:764–765
  12. Griffey SM, Kraegel SA, Madewell BR. Rapid detection of K-ras gene mutations in canine lung cancer using single-strand conformational polymorphism analysis. Carcinogenesis. 1998;19:959–963
  13. Griffey SM, Kraegel SA, Weller RE, Watson CR, Madewell BR. K-ras mutations in 239PuO2 canine lung neoplasms. Cancer Lett. 1998;132:1–5
  14. Kraegel SA, Gumerlock PH, Dungworth DL, Oreffo VI, Madewell BR. K-ras activation in non-small cell lung cancer in the dog. Cancer Res. 1992;52:4724–4727
  15. Mayr B, Schaffner G, Reifinger M. K-ras mutations in canine pancreatic cancers. Vet Rec. 2003;153:87–89
  16. Edwards MD, Pazzi KA, Gumerlock PH, Madewell BR. c-N-ras is activated infrequently in canine malignant lymphoma. Toxicol Pathol. 1993;21:288–291
  17. Mayr B, Holzheu M, Schaffner G, Reifinger M. N-ras mutation in a canine lymphoma: short communication. Acta Vet Hung. 2003;51:91–94
  18. Mayr B, Winkler G, Schaffner G, Reifinger M, Brem G. N-ras mutation in a feline lymphoma. Low frequency of N-ras mutations in a series of feline, canine and bovine lymphomas. Vet J. 2002;163:326–328
  19. Watzinger F, Mayr B, Gamerith R, Vetter C, Lion T. Comparative analysis of ras proto-oncogene mutations in selected mammalian tumors. Mol Carcinog. 2001;30:190–198
  20. Gumerlock PH, Meyers FJ, Foster BA, Kawakami TG, deVere White RW. Activated c-N-ras in radiation-induced acute nonlymphocytic leukemia: twelfth codon aspartic acid. Radiat Res. 1989;117:198–206
  21. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–1542
  22. Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 1992;80:2584–2593
  23. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907–3914
  24. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494–1504
  25. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66
  26. Nakao M, Janssen JW, Erz D, Seriu T, Bartram CR. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia. 2000;14:522–524
  27. Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155–162
  28. Stirewalt DL, Meshinchi S, Kussick SJ, et al. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. Br J Haematol. 2004;124:481–484
  29. Andersson A, Johansson B, Lassen C, Mitelman F, Billstrom R, Fioretos T. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol. 2004;72:307–313
  30. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434–2439
  31. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085–1088
  32. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335
  33. Syampurnawati M, Tatsumi E, Furuta K, Hayashi Y. Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene. Leuk Res. 2007;31;877
  34. Bianchini M, Ottaviani E, Grafone T, et al. Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. Clin Chem. 2003;49:1642–1650
  35. Zavodovskaya R, Liao AT, Jones CL, et al. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. Am J Vet Res. 2006;67:633–641
  36. Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma. 1998;30:459–466
  37. Sperling C, Schwartz S, Buchner T, Thiel E, Ludwig WD. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica. 1997;82:617–621
  38. Kitayama H, Tsujimura T, Matsumura I, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood. 1996;88:995–1004
  39. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920–925
  40. Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806–1809
  41. Shimada A, Taki T, Kubota C, et al. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group. Leukemia. 2007;21:2218–2219
  42. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19:1536–1542
  43. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121:775–777
  44. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23:16–43
  45. London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999;27:689–697
  46. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood. 2006;108:3504–3513
  47. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005;102:1104–1109
  48. Lorenzo F, Nishii K, Monma F, Kuwagata S, Usui E, Shiku H. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Leuk Res. 2006;30:1235–1239
  49. Kimura A, Nakata Y, Katoh O, Hyodo H. c-kit Point mutation in patients with myeloproliferative disorders. Leuk Lymphoma. 1997;25:281–287
  50. Cairoli R, Grillo G, Beghini A, Cornacchini G, Larizza L, Morra E. Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis. Hematol J. 2004;5:273–275
  51. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol. 2007;44:298–308
  52. Frost D, Lasota J, Miettinen M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet Pathol. 2003;40:42–54
  53. Auewarakul CU, Lauhakirti D, Tocharoentanaphol C. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Eur J Haematol. 2006;77:51–56
  54. Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood. 1990;75:1684–1690
  55. Rovera G, Reichard BA, Hudson S, et al. Point mutations in both transforming and non-transforming codons of the N-ras proto-oncogene of Ph+ leukemias. Oncogene. 1989;4:867–872
  56. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106:2113–2119
  57. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–3595
  58. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107:3847–3853
  59. Nakamura H, Inokuchi K, Yamaguchi H, Dan K. Abnormalities of p51, p53, FLT3 and N-ras genes and their prognostic value in relapsed acute myeloid leukemia. J Nippon Med Sch. 2004;71:270–278
  60. Bar-Eli M, Ahuja H, Foti A, Cline MJ. N-RAS mutations in T-cell acute lymphocytic leukaemia: Analysis by direct sequencing detects a novel mutation. Br J Haematol. 1989;72:36–39
  61. Cogswell PC, Morgan R, Dunn M, et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood. 1989;74:2629–2633
  62. Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603–1611
  63. Browett PJ, Yaxley JC, Norton JD. Activation of Harvey ras oncogene by mutation at codon 12 is very rare in hemopoietic malignancies. Leukemia. 1989;3:86–88
  64. Imamura N, Kuramoto A, Ishihara H, Shimizu S. Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia. Am J Hematol. 1993;43:151–153
  65. Watzinger F, Mayr B, Haring E, Lion T. High sequence similarity within ras exons 1 and 2 in different mammalian species and phylogenetic divergence of the ras gene family. Mamm Genome. 1998;9:214–219
  66. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20:965–970
  67. Yamamoto T, Isomura M, Xu Y, et al. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk Res. 2006;30:1085–1089
  68. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113:983–988
  69. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54:3–24
  70. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol. 1999;112:165–170
  71. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002;100:585–593
  72. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865–2870
  73. Hongyo T, Li T, Syaifudin M, et al. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 2000;60:2345–2347
  74. Riva F, Brizzola S, Stefanello D, Crema S, Turin L. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J Vet Diagn Invest. 2005;17:385–388
  75. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol. 2002;39:529–535
  76. De Melo MB, Lorand-Metze I, Lima CS, Saad ST, Costa FF. N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis. Leuk Lymphoma. 1997;24:309–317
  77. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190–195
  78. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007;6:149–165
  79. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin Oncol. 2001;28:9–18
  80. Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007;110:1178–1186
  81. Cairoli R, Beghini A, Morello E, et al. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. Leuk Res. 2005;29:397–400
  82. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res. 2003;9:2755–2768
  83. Dobson J, Villiers E, Morris J. Diagnosis and management of leukaemia in dogs and cats. In Pract. 2006;28:22–31
  84. Lee YY, Kim WS, Bang YJ, et al. Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. Stem Cells. 1995;13:556–563
  85. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008;111:4788–4796
  86. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25:1434–1436
  87. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–266
  88. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148–150
  89. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19:2232–2240
  90. Thorn J, Molloy P, Iland H. SSCP detection of N-ras promoter mutations in AML patients. Exp Hematol. 1995;23:1098–1103
  91. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27:263–270
  92. Roumier C, Eclache V, Imbert M, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood. 2003;101:1277–1283
  93. Forbes LV, Gale RE, Pizzey A, Pouwels K, Nathwani A, Linch DC. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene. 2002;21:5981–5989
  94. Breen M, Bullerdiek J, Langford CF. The DAPI banded karyotype of the domestic dog (Canis familiaris) generated using chromosome-specific paint probes. Chromosome Res. 1999;7:401–406
  95. Horsting N, Wohlsein P, Reimann N, Bartnitzke S, Bullerdiek J, Nolte I. Cytogenetic analysis of three oropharyngeal malignant melanomas in dogs. Res Vet Sci. 1999;67:149–151
  96. Reimann N, Bartnitzke S, Bullerdiek J, Mischke R, Nolte I. Trisomy 1 in a canine acute leukemia indicating the pathogenetic importance of polysomy 1 in leukemias of the dog. Cancer Genet Cytogenet. 1998;101:49–52
  97. Grindem CB, Buoen LC. Cytogenetic analysis of leukaemic cells in the dog. A report of 10 cases and a review of the literature. J Comp Pathol. 1986;96:623–635
  98. Nolte M, Werner M, Nolte I, Georgii A. Different cytogenetic findings in two clinically similar leukaemic dogs. J Comp Pathol. 1993;108:337–342
  99. Nolte I, Reimann N, Bullerdiek J, Bartnitzke S, Mischke R, Nolte M. Importance of cytogenetic investigations in canine leukemias]. Tierarztl Prax. 1997;25:393–397
  100. Darre R, Queinnec G, Guelfi J-F, Florio R, Colombies P, Berland HM. Constance d'un chromosome particulier dans un cas de leukemie chez le chien. Ann Recherches Vet. 1970;1:93–106
  101. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans: man and his best friend share more than companionship. Chromosome Res. 2008;16:145–154

PII: S0301-472X(08)00433-5

doi: 10.1016/j.exphem.2008.09.005

Experimental Hematology
Volume 37, Issue 1 , Pages 65-77 , January 2009

Article Tools

* Image Usage & Resolution